Kirichenko Alexander, Uemura Tadahiro, Liang Yun, Hasan Shaakir, Abel Steven, Renz Paul, Shamsesfandabadi Parisa, Carpenter Jennifer, Yin Yue, Thai Ngoc
Division of Radiation Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania.
Division of Abdominal Transplantation and Hepato-Biliary Surgery, Allegheny General Hospital, Pittsburgh, Pennsylvania.
Adv Radiat Oncol. 2023 Sep 1;9(2):101367. doi: 10.1016/j.adro.2023.101367. eCollection 2024 Feb.
We report on the feasibility and outcomes of liver stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC) with single-photon emission computed tomography (SPECT) functional treatment planning in patients with Child-Pugh (CP) B/C cirrhosis.
Liver SPECT with Tc-sulfur colloid was coregistered to treatment planning computed tomography (CT) for the guided avoidance of functional hepatic parenchyma during SBRT. Functional liver volumes (FLVs) obtained from SPECT were compared with anatomic liver volumes defined on the planning CT. Radiation dose constraints were adapted exclusively to FLV. Local control, toxicity, and survival were reported with at least 6 months of radiographic follow-up. Pre- and posttransplant outcomes were analyzed in a subset of patients who completed SBRT as a bridge to liver transplant. Model of End-Stage Liver Disease was used to score hepatic function before and after SBRT completion.
With a median follow-up of 32 months, 45 patients (58 lesions) with HCC and CP-B/C cirrhosis received SBRT to a median dose of 45 Gy (3-5 fractions). FLV loss (34%, < .001) was observed in all patients, and the functional and anatomic liver volumes matched well in a control group of noncirrhotic/non-HCC patients. Despite marked functional parenchyma retraction, the amount of FLV on SPECT exposed to the threshold irradiation was significantly less than the CT liver volumes ( < .001) because of the optimized beam placement during dosimetry planning. Twenty-three patients (51%) successfully completed orthotopic liver transplant, with a median time to transplant of 9.2 months. With 91% in-field local control, the overall 2-year survival was 65% (90% after the orthotopic liver transplant), with no incidence of radiation-induced liver disease observed within 3 to 4 months or accelerated CP class migration from B to C within the first 6 months post-SBRT. Mean Model of End-Stage Liver Disease-Na score was not significantly elevated at 3-month intervals after SBRT completion.
Functional treatment planning with Tc sulfur colloid SPECT/CT allows identification and avoidance of functional hepatic parenchyma in patients with CP-B/C cirrhosis, leading to low toxicity and satisfactory transplant outcomes.
我们报告了在Child-Pugh(CP)B/C级肝硬化患者中,采用单光子发射计算机断层扫描(SPECT)功能治疗计划进行肝细胞癌(HCC)肝脏立体定向体部放射治疗(SBRT)的可行性和结果。
将锝硫胶体肝脏SPECT与治疗计划计算机断层扫描(CT)进行配准,以在SBRT期间引导避开功能性肝实质。将从SPECT获得的功能性肝脏体积(FLV)与计划CT上定义的解剖学肝脏体积进行比较。放射剂量限制专门根据FLV进行调整。报告了至少6个月影像学随访后的局部控制、毒性和生存率。对作为肝移植桥梁完成SBRT的患者亚组分析了移植前后的结果。使用终末期肝病模型对SBRT完成前后的肝功能进行评分。
中位随访32个月,45例(58个病灶)HCC和CP-B/C级肝硬化患者接受了SBRT,中位剂量为45 Gy(3 - 5次分割)。所有患者均观察到FLV减少(34%,P <.001),并且在非肝硬化/非HCC患者对照组中,功能性和解剖学肝脏体积匹配良好。尽管功能性实质明显回缩,但由于剂量测定计划期间优化了射束放置,SPECT上暴露于阈值照射的FLV量明显小于CT肝脏体积(P <.001)。23例患者(51%)成功完成原位肝移植,中位移植时间为9.2个月。局部野内控制率为91%,总体2年生存率为65%(原位肝移植后为90%),在SBRT后3至4个月内未观察到放射性肝病的发生,且在最初6个月内未观察到CP分级从B级加速迁移至C级。SBRT完成后3个月间隔时,终末期肝病-Na评分均值无显著升高。
采用锝硫胶体SPECT/CT进行功能治疗计划可识别并避开CP-B/C级肝硬化患者的功能性肝实质,从而导致低毒性和令人满意的移植结果。